Obtenga las últimas noticias sobre las acciones de Bright Minds Biosciences con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de DRUG

Últimas noticias sobre

Bright Minds Biosciences

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences Inc

DRUG FREE SOLUTION INC by Drug Free Solution Inc.

Drug Free Solution Inc

Drugs Made In America Acquisition Corp. - Ordinary Shares

Drugs Made In America Acquisition Corp

Drugs Made In America Acquisition Corp. - Units

Drugs Made In America Acquisition Corp. - Rights

Press Releases

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

News

Health Care

Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

Management

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

General

Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101

Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

AIFF

CSE:DRUG

DRUG

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Altimmune

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Benitec Biopharma

Candel Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

CytomX Therapeutics

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

DiaMedica Therapeutics Inc. - Common Stock

DiaMedica Therapeutics

Design Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Foghorn Therapeutics

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Humacyte

Inhibrx Biosciences

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Neurogene

Ocugen

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Comments

Bright Minds Biosciences Noticias bursátiles

Noticias

Últimas noticias sobre

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL